Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Pneumococcal 7-Valent Conjugate Vaccine

Vaccine (Recombinant protein vaccine) · Immune activation, directed at Streptococcus pneumoniae capsular polysaccharide serotypes 4, 6B, 9V, 14, 18C, 1 · developed by Valneva Austria GmbH

Phase 3 Most advanced trial (none active)

VALN Developer

1 Registered trials

What is Pneumococcal 7-Valent Conjugate Vaccine?

Pneumococcal 7-Valent Conjugate Vaccine is an active immunizing agent made of saccharides from the capsules of seven Streptococcus pneumoniae serotypes, each conjugated to diphtheria CRM197 protein. It is intended to prevent infection by Streptococcus pneumoniae. It is also studied in encephalitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Prevnar
Drug type: Vaccine (Recombinant protein vaccine)
Targets: Streptococcus pneumoniae capsular polysaccharide serotypes 4, 6B, 9V, 14, 18C, 1 (antigen)
Mechanism: Immune activation, directed at Streptococcus pneumoniae capsular polysaccharide serotypes 4, 6B, 9V, 14, 18C, 1
Therapy area: Neurology
Developer: Valneva Austria GmbH (VALN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01041573	Phase 3	Encephalitis	Completed	VALN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Encephalitis

More from Valneva Austria GmbH

IC51 FDA approved Japanese encephalitis virus vaccine, inactivated FDA approved 3M-052-AF Phase 1 ChAdOx1 nCoV-19 Vaccine Phase 3 IC41 Phase 2 IC43 Phase 2/3 IC47 Phase 1 IC84 Phase 1 ISS 1018 CpG Oligodeoxynucleotide Phase 1 JE-VAX Phase 3 VLA1553 Phase 3 VLA1601 Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the VALN page.

Follow VALN, the company behind Pneumococcal 7-Valent Conjugate Vaccine

See VALN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VALN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z